Author results

1M27
  • Download 1m27
  • View 1m27
Molmil generated image of 1m27
CRYSTAL STRUCTURE OF SAP/FYNSH3/SLAM TERNARY COMPLEX
Descriptor:SH2 domain protein 1A, Signaling lymphocytic activation molecule, Proto-oncogene tyrosine-protein kinase FYN, ...
Authors:Chan, B., Griesbach, J., Song, H.K., Poy, F., Terhorst, C., Eck, M.J.
Deposit date:2002-06-21
Release date:2003-05-06
Last modified:2011-07-13
Method:X-RAY DIFFRACTION (2.5 Å)
Cite:SAP couples Fyn to SLAM immune receptors.
NAT.CELL BIOL., 5, 2003
2QRZ
  • Download 2qrz
  • View 2qrz
Molmil generated image of 2qrz
CDC42 BOUND TO GMP-PCP: INDUCED FIT BY EFFECTOR IS REQUIRED
Descriptor:Cell division control protein 42 homolog precursor, MAGNESIUM ION, SULFATE ION, ...
Authors:Phillips, M.J., Calero, G., Chan, B., Cerione, R.A.
Deposit date:2007-07-30
Release date:2008-03-18
Last modified:2011-07-13
Method:X-RAY DIFFRACTION (2.4 Å)
Cite:Effector Proteins Exert an Important Influence on the Signaling-active State of the Small GTPase Cdc42.
J.Biol.Chem., 283, 2008
5C8K
  • Download 5c8k
  • View 5c8k
Molmil generated image of 5c8k
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 1
Descriptor:Epidermal growth factor receptor, 1-cyclopentyl-N-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-1H-imidazo[4,5-c]pyridin-6-amine
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-25
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (3 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5C8M
  • Download 5c8m
  • View 5c8m
Molmil generated image of 5c8m
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 17
Descriptor:Epidermal growth factor receptor, 2-methyl-N-{2-[4-(methylsulfonyl)piperidin-1-yl]pyrimidin-4-yl}-1-(propan-2-yl)-1H-imidazo[4,5-c]pyridin-6-amine
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-25
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.9 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5C8N
  • Download 5c8n
  • View 5c8n
Molmil generated image of 5c8n
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 23
Descriptor:Epidermal growth factor receptor, SULFATE ION, N-{2-[4-(2-aminoethyl)-4-methoxypiperidin-1-yl]pyrimidin-4-yl}-2-methyl-1-(propan-2-yl)-1H-imidazo[4,5-c]pyridin-6-amine
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-25
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.401 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5CAL
  • Download 5cal
  • View 5cal
Molmil generated image of 5cal
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 24
Descriptor:Epidermal growth factor receptor, 2,2-dimethyl-3-[(4-{[2-methyl-1-(propan-2-yl)-1H-imidazo[4,5-c]pyridin-6-yl]amino}pyrimidin-2-yl)amino]propanamide
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-29
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.7 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5CAN
  • Download 5can
  • View 5can
Molmil generated image of 5can
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 27
Descriptor:Epidermal growth factor receptor, SULFATE ION, (3R)-3-methyl-1-(4-{[2-methyl-1-(propan-2-yl)-1H-imidazo[4,5-c]pyridin-6-yl]amino}pyrimidin-2-yl)pyrrolidine-3-carboxamide
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-29
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.8 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5CAO
  • Download 5cao
  • View 5cao
Molmil generated image of 5cao
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 29
Descriptor:Epidermal growth factor receptor, N~2~-[2-methyl-2-(methylsulfonyl)propyl]-N~4~-[2-methyl-1-(propan-2-yl)-1H-imidazo[4,5-c]pyridin-6-yl]pyrimidine-2,4-diamine
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-29
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.6 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5CAP
  • Download 5cap
  • View 5cap
Molmil generated image of 5cap
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 30
Descriptor:Epidermal growth factor receptor, SULFATE ION, 2-methyl-N-[2-(2-methyl-2-methylsulfonyl-propoxy)pyrimidin-4-yl]-1-propan-2-yl-imidazo[4,5-c]pyridin-6-amine
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-29
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.4 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5CAQ
  • Download 5caq
  • View 5caq
Molmil generated image of 5caq
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 33
Descriptor:Epidermal growth factor receptor, SULFATE ION, N-[2-[(3R,4S)-3-fluoranyl-4-methoxy-piperidin-1-yl]pyrimidin-4-yl]-2-methyl-1-propan-2-yl-imidazo[4,5-c]pyridin-6-amine
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-29
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.5 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5CAS
  • Download 5cas
  • View 5cas
Molmil generated image of 5cas
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 41A
Descriptor:Epidermal growth factor receptor, SULFATE ION, (1R)-1-{6-({2-[(3R,4S)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl}amino)-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-imidazo[4,5-c]pyridin-2-yl}ethanol
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-29
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.1 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5CAU
  • Download 5cau
  • View 5cau
Molmil generated image of 5cau
EGFR KINASE DOMAIN MUTANT "TMLR" WITH COMPOUND 41B
Descriptor:Epidermal growth factor receptor, SULFATE ION, (1R)-1-{6-({2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl}amino)-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-imidazo[4,5-c]pyridin-2-yl}ethanol
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-29
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.25 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5CAV
  • Download 5cav
  • View 5cav
Molmil generated image of 5cav
EGFR KINASE DOMAIN WITH COMPOUND 41A
Descriptor:Epidermal growth factor receptor, (1R)-1-{6-({2-[(3R,4S)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl}amino)-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-imidazo[4,5-c]pyridin-2-yl}ethanol
Authors:Eigenbrot, C., Yu, C.
Deposit date:2015-06-30
Release date:2015-10-28
Last modified:2015-12-02
Method:X-RAY DIFFRACTION (2.73 Å)
Cite:Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
J.Med.Chem., 58, 2015
5SYB
  • Download 5syb
  • View 5syb
Molmil generated image of 5syb
CRYSTAL STRUCTURE OF HUMAN PHF5A
Descriptor:PHD finger-like domain-containing protein 5A, ZINC ION, 1,2-ETHANEDIOL
Authors:Tsai, J.H.C., Teng, T., Zhu, P., Fekkes, P., Larsen, N.A.
Deposit date:2016-08-10
Release date:2016-09-07
Last modified:2017-06-07
Method:X-RAY DIFFRACTION (1.82 Å)
Cite:Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.
Nat Commun, 8, 2017
5ZYA
  • Download 5zya
  • View 5zya
Molmil generated image of 5zya
SF3B SPLICEOSOMAL COMPLEX BOUND TO E7107
Descriptor:Splicing factor 3B subunit 5, Splicing factor 3B subunit 1, PHD finger-like domain-containing protein 5A, ...
Authors:Finci, L.I., Larsen, N.A.
Deposit date:2018-05-23
Release date:2018-06-20
Method:ELECTRON MICROSCOPY (3.95 Å)
Cite:The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action
Genes Dev., 32, 2018